Answer: Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications that includes semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro), liraglutide (Victoza, Saxenda), and orforglipron (Foundayo), have become increasingly popular for obesity treatment (Mehrtash, JAMA Intern Med 2025)
by 2022 but has been honest about her weight changing during more stressful times in her life
In this landscape, Wegovy has emerged as a promising addition to our arsenal of obesity treatments
Reduced levels of nitric oxide contribute to vasoconstriction (blood vessel narrowing) and increased blood pressure
By reducing gluconeogenesis, semaglutide further supports the bodys ability to maintain healthy blood sugar levels, which is crucial for weight management and overall metabolic health
Serious toxicity may affect blood, bone marrow, liver, pancreas, and brain